HOLMES BIOPHARMA ENTERS INTO AGREEMENT TO ACQUIRE DRUG RESEARCH AND DEVELOPMENT BUSINESS

Holmes Herbs, Inc., (OTCBB:HMHB), announced today that it has entered into an agreement to purchase a controlling interest in Qualia Clinical Research Services Ltd. ("Qualia"). Under the terms of the agreement, the Company, via its Holmes Biopharma division, will fund a minimum of US$1,500,000 to expand Qualia's existing clinical drug research business. The acquisition is set to close on or before November 30, 2005. Qualia is managed by an experienced group of doctors and scientists. Dr. Sohail Khattak, MD, President and CEO of Qualia, has served as an advisory board member for leading drug companies including Abbot, Novartis, Jansen Ortho and Shire Pharmaceuticals.

CCNMatthews (http://www.ccnmatthews.com/news/releasesfr/show.jsp?action=showRelease&actionFor=554242)